Cardiogen

Cardiogen is a short synthetic peptide bioregulator from the Khavinson peptide medicine program, a family that also includes Thymogen, Vilon, Pinealon, Vesugen, Epitalon, and Bronchogen Peptide medicines: past, present, future. It belongs to a group of ultrashort peptides made of just 2 to 7 amino acids Peptide Regulation of Gene Expression: A Systematic Review+1. The main research focus is cardiac tissue regulation, especially how heart tissue responds to stress and aging IMPACT OF CARDIOGEN INJECTION IN THE ADRENALINE-INDUCED STRESS MODEL ON THE RATE OF THE HEART INDEX AND WEIGHTED PARAMETERS OF RAT BODIES+2.

The evidence base is preclinical. In a rat model of adrenaline-induced stress, Cardiogen injection normalized heart rate and reduced arrhythmia manifestations, while also compensating for stress-related changes in heart, adrenal, and spleen weight IMPACT OF CARDIOGEN INJECTION IN THE ADRENALINE-INDUCED STRESS MODEL ON THE RATE OF THE HEART INDEX AND WEIGHTED PARAMETERS OF RAT BODIES. In organotypic tissue culture, Cardiogen influenced myocardial tissue development from young and old rats [The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats]+1. These findings support a tissue-level regulatory role, but there are no human clinical trials in the available corpus Peptide medicines: past, present, future.

Cardiogen is not a classic lock-and-key receptor drug. It appears to work mainly at the cell nucleus, where gene activity is controlled. Short peptides in this family can enter the cell and nucleus, interact with DNA and histone proteins, and influence gene expression Peptide medicines: past, present, future. In plain terms, Cardiogen may change which cardiac genes are turned on or off, especially genes involved in heart muscle cell maintenance, stress adaptation, and repair IMPACT OF CARDIOGEN INJECTION IN THE ADRENALINE-INDUCED STRESS MODEL ON THE RATE OF THE HEART INDEX AND WEIGHTED PARAMETERS OF RAT BODIES+1.

Cell entry appears to rely on peptide transporters. Di- and tripeptides can be carried into cells by PEPT1, PEPT2, PHT1, PHT2, LAT1, and LAT2 Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. This helps explain how very short peptides may reach specific tissues. Cardiogen's reported myocardial tissue specificity in organotypic culture fits this model, but formal human pharmacokinetic data are missing [The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats]+2.

A secondary action is more system-level. In the rat stress model, Cardiogen injection reduced stress-induced heart rate elevation and arrhythmic signs IMPACT OF CARDIOGEN INJECTION IN THE ADRENALINE-INDUCED STRESS MODEL ON THE RATE OF THE HEART INDEX AND WEIGHTED PARAMETERS OF RAT BODIES. That suggests an adaptogenic or autonomic-stabilizing effect alongside direct gene regulation IMPACT OF CARDIOGEN INJECTION IN THE ADRENALINE-INDUCED STRESS MODEL ON THE RATE OF THE HEART INDEX AND WEIGHTED PARAMETERS OF RAT BODIES. Short peptides in this class have also been described as regulating DNA methylation, an epigenetic switch that can silence or activate genes Peptide medicines: past, present, future.

The available evidence comes from animal and tissue-culture work, so it is directional rather than proof of human benefit.

Cardiac stress protection: In an adrenaline-induced stress model, Cardiogen injection moved heart rate back toward control values and reduced arrhythmia manifestations IMPACT OF CARDIOGEN INJECTION IN THE ADRENALINE-INDUCED STRESS MODEL ON THE RATE OF THE HEART INDEX AND WEIGHTED PARAMETERS OF RAT BODIES. It also normalized stress-related changes in relative heart, adrenal, and spleen mass IMPACT OF CARDIOGEN INJECTION IN THE ADRENALINE-INDUCED STRESS MODEL ON THE RATE OF THE HEART INDEX AND WEIGHTED PARAMETERS OF RAT BODIES. This is the strongest functional effect in the corpus, but it is a single rat study with unknown dosing details.

Myocardial tissue development: In organotypic myocardium cultures from young and old rats, Cardiogen and amino acids influenced tissue development [The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats]+1. The age-dependent effect suggests a role in age-related cardiac tissue regulation, but it is in vitro evidence.

Tumor-modifying effect: One senescent rat study tested cardiogen peptide in an M-1 sarcoma model and reported a tumor-modifying effect Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats. The direction and clinical meaning are unclear because the abstract does not provide details Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats.

Gene expression regulation: Mechanistic reviews describe how short peptides can interact with DNA and histones and alter gene promoter activity Peptide medicines: past, present, future+1. This is proposed mechanism, not a clinical outcome.

Published animal studies provide only qualitative protocols. The rat stress model used injection around stress exposure, but the abstracts do not report exact doses IMPACT OF CARDIOGEN INJECTION IN THE ADRENALINE-INDUCED STRESS MODEL ON THE RATE OF THE HEART INDEX AND WEIGHTED PARAMETERS OF RAT BODIES. Tissue-culture studies added Cardiogen to myocardium tissue from young and old rats [The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats]+1.

Because no human clinical protocol exists in the corpus, the most common research-facing schedules come from practitioner convention rather than trial data.

Route	Dose	Frequency	Duration	Evidence
Subcutaneous or intramuscular	10 mg	Every 1-3 days	10-20 days	Community protocol
Oral	10 mg	1-2 times daily	30 days	Community protocol
Rat stress injection	Not stated	Around stress exposure	Acute	Animal study [source:2]
Rat myocardium tissue culture	Amino acids plus Cardiogen	In vitro	Not stated	In vitro [source:3]

No weight-adjusted human dosing data exist. The available animal abstracts do not report milligram-per-kilogram doses IMPACT OF CARDIOGEN INJECTION IN THE ADRENALINE-INDUCED STRESS MODEL ON THE RATE OF THE HEART INDEX AND WEIGHTED PARAMETERS OF RAT BODIES+1.

Cardiogen is supplied as a lyophilized powder. No published Cardiogen-specific reconstitution protocol exists, so handling follows standard peptide practice Peptide medicines: past, present, future. The diluent of record in community protocols is bacteriostatic water, which contains 0.9% benzyl alcohol to reduce bacterial growth.

To prepare, use aseptic technique. Inject the diluent slowly against the vial wall and swirl gently rather than shaking. After the powder dissolves, store the reconstituted solution in the refrigerator at 2-8°C and do not freeze it [The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats]+1. Community practice is to use the reconstituted solution within 7 to 14 days.

For exact volumes and concentration calculations, use the interactive reconstitution calculator in this section. It handles the dilution math from vial size, diluent volume, and desired dose.

No human drug-interaction studies for Cardiogen were identified in the available corpus. The profile below combines limited animal data with mechanistic reasoning from peptide transport.

Sympathomimetics: In a rat adrenaline stress model, Cardiogen blunted heart-rate and arrhythmia changes IMPACT OF CARDIOGEN INJECTION IN THE ADRENALINE-INDUCED STRESS MODEL ON THE RATE OF THE HEART INDEX AND WEIGHTED PARAMETERS OF RAT BODIES. Theoretically, Cardiogen could reduce the expected heart-rate response to epinephrine, norepinephrine, albuterol, pseudoephedrine, or high-dose caffeine. This is based on one animal model, not human data.

Beta-blockers and other negative chronotropes: Because Cardiogen slowed stress-induced tachycardia in rats, additive bradycardia with beta-blockers, ivabradine, or calcium-channel blockers is a theoretical concern IMPACT OF CARDIOGEN INJECTION IN THE ADRENALINE-INDUCED STRESS MODEL ON THE RATE OF THE HEART INDEX AND WEIGHTED PARAMETERS OF RAT BODIES. No interaction study confirms this.

Transporter competition: Short peptides can use PEPT1, PEPT2, LAT1, and LAT2 for cellular uptake Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. Cardiogen may share these uptake routes with other small peptides, certain amino acid derivatives, or a high-protein meal. For oral research protocols, spacing from meals by 30 to 60 minutes has been proposed to reduce competition Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers.

Epigenetic drugs: Short peptides can interact with histones and DNA Peptide medicines: past, present, future+1. The interaction with drugs that alter DNA methylation or histone acetylation is unknown and should be avoided outside formal study.

No study has demonstrated that Cardiogen causes receptor desensitization or tachyphylaxis. Instead, cycling follows the short-course design used in animal studies and general peptide bioregulator practice IMPACT OF CARDIOGEN INJECTION IN THE ADRENALINE-INDUCED STRESS MODEL ON THE RATE OF THE HEART INDEX AND WEIGHTED PARAMETERS OF RAT BODIES+1.

Community injectable protocols typically use 10 mg every 1 to 3 days for 10 to 20 days, followed by 5 to 10 days off, then repeat for 2 to 3 cycles. Some protocols use 100 to 200 mcg daily for 20 days on and 10 days off. These are practitioner conventions, not trial-derived schedules.

The rationale is that animal studies used short-term injection rather than chronic daily exposure IMPACT OF CARDIOGEN INJECTION IN THE ADRENALINE-INDUCED STRESS MODEL ON THE RATE OF THE HEART INDEX AND WEIGHTED PARAMETERS OF RAT BODIES. Short-course intermittent exposure may reduce continuous pathway activation, but this is general peptide practice, not Cardiogen-specific evidence.

Signs that a break may be needed include diminishing benefit after 2-3 cycles, return of baseline symptoms, or new injection-site reactions. A typical off period after 2-3 cycles is 4-8 weeks before restarting.

Cardiogen is sometimes discussed alongside other peptides, but no direct co-administration studies exist. The rationale is usually functional: pair a cardiac bioregulator with tissue-repair peptides or other Khavinson bioregulators.

With BPC-157 and TB-500: These repair peptides act through angiogenic and cytoprotective pathways, while Cardiogen is gene-regulatory. A theoretical synergy for cardiac repair has been proposed, but not tested IMPACT OF CARDIOGEN INJECTION IN THE ADRENALINE-INDUCED STRESS MODEL ON THE RATE OF THE HEART INDEX AND WEIGHTED PARAMETERS OF RAT BODIES+1. Community practice tends to alternate cycles rather than inject them at the same time.

With other Khavinson bioregulators: Thymalin, Epithalamin, Cortexin, Vilon, Pinealon, Epitalon, Bronchogen, and Cardiogen share gene-expression mechanisms Peptide medicines: past, present, future+1. Concurrent use could create overlapping or unpredictable transcriptional effects. Community practice is to use one bioregulator at a time or separate them by 4 to 6 hours.

With growth hormone secretagogues: No evidence of interaction exists. Because many short peptides use PEPT1/LAT transporters, spacing for oral uptake may reduce competition Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers.

There are no human stacking studies, so any combination is experimental.

Cardiogen is not approved by the FDA, EMA, or other major regulatory authorities as a therapeutic drug. It appears in the scientific literature as a synthetic peptide bioregulator under investigation rather than as a licensed pharmaceutical Peptide medicines: past, present, future. No human clinical trial or marketing authorization was identified in the available corpus.

In the United States, Cardiogen is not scheduled under the Controlled Substances Act, but it falls into the category of an unapproved drug when sold for human therapeutic use. It is not legal to sell as a dietary supplement or research chemical without an approved application. These classifications are based on regulatory inference from its unapproved status.

For athletes, Cardiogen's status is not explicitly listed in the available sources. Because it lacks government approval for human therapeutic use, it would likely fall under WADA category S0, which prohibits substances that are not approved for human use. Athletes should assume it is prohibited in and out of competition.

No human safety data for Cardiogen exist in the available corpus. The only in vivo safety-related evidence is from a rat stress model, where Cardiogen injection normalized heart rate and reduced arrhythmia signs during adrenaline stress IMPACT OF CARDIOGEN INJECTION IN THE ADRENALINE-INDUCED STRESS MODEL ON THE RATE OF THE HEART INDEX AND WEIGHTED PARAMETERS OF RAT BODIES. These were reported as therapeutic effects, not adverse events.

Tissue-culture studies showed development-promoting activity without reported cytotoxicity [The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats]+1. Local injection-site reactions are plausible for any injectable peptide, but none are documented in the corpus.

Theoretical concerns include exaggerated bradycardia or hypotension because of the heart-rate-lowering activity seen in stressed rats IMPACT OF CARDIOGEN INJECTION IN THE ADRENALINE-INDUCED STRESS MODEL ON THE RATE OF THE HEART INDEX AND WEIGHTED PARAMETERS OF RAT BODIES. There is also a tumor-modifying signal in one senescent rat sarcoma model, but the direction and human relevance are unknown Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats. Avoid assuming neutrality in oncology settings.

Special populations have no safety data. Pregnancy, lactation, pediatric, and active malignancy are generally avoided outside formal study. Monitoring in community practice typically includes heart rate, blood pressure, and an ECG before use because of the cardiac target.